Read by QxMD icon Read


G Zanierato, E Ranghino, L Negri, G C Morandini
A comparative trial conducted on 48 male and 9 female patients suitably selected in terms of indication consisted of a first stage in which a completely random, doubleblind comparison was made between acetylsalicylic acid, guacetisal and guaiacol carbonate (preparations A, B, and C) while in the second stage an association of bromexine, acetylsalicylic acid and codeine phosphate (preparation D) was examined in terms of activity and tolerance in an open trial. Statistical analysis showed the superiority of preparation B with respect to most of the parameters taken into consideration...
February 28, 1981: Minerva Medica
C Daroda, C Galluzzo, R Porzia, E Riva, M Giovannini
The therapeutic effectiveness of a new antiinflammatory-expectorant drug, guacetisal (Broncaspin) has been compared with that of a well known mucolytic, bromexine, already available for therapy, in the paediatric suspension formula. The study was carried out on 26 children in the 1st Paediatrics clinic of Milan University. The children were suffering from inflammation of the respiratory apparatus. It is concluded that the new drug possesses greated clinical effectiveness.
February 28, 1981: Minerva Medica
S Caltagirone, M Vagliasindi, F Palermo, G U Di Maria, N Crimi, F Cusmano
Controlled clinical research has been carried out on the activity and tolerance of a new active principle, guacetisal (Broncaspin) obtained from the esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic bronchitis. The drug's therapeutic response was evaluated with respect to that of bromexine. Guacetisal was generally well tolerated. It had no unwanted side-effects on the main haematochemical parameters or on the function of organs and systems. It was found to have considerable therapeutic effectiveness, at times even superior to that of the control drug, with respect to general symptomatology and at respiratory system level...
February 28, 1981: Minerva Medica
D Olivieri, M Bocchino, M Caputi
No abstract text is available yet for this article.
November 1970: Archivio Monaldi Per la Tisiologia e le Malattie Dell'apparato Respiratorio
P Banna, M F Marcello, R Murabito, A Saggio, M Riggi, C CinĂ , S Latteri
The authors describe the ultrastructural alterations of the pulmonary parenchyma produced in dogs by endotoxic shock, and they examine the effects that a 'secretolytic' drug (bromexine) has in modifying those changes. In the animals under shock there is a complete breakdown of the normal structure of the pulmonary parenchyma. According to the authors, these lesions are caused by the damage of the lining layer and of the cells which produce the constituents of the surfactant system. In dogs under shock and treated with bromexine the authors have seen a better organization of the pulmonary parenchyma: the cellular limits of the pneumocytes of types I and II were more clearly defined and the osmiophilic bodies were increased both in number and volume...
1985: Respiration; International Review of Thoracic Diseases
R Scuri, P Mondani, C Frova, L Fantini
A new, original molecule, nesosteine, modified both the rheology and the production of tracheobronchial mucus in rabbits. The drug highly significantly reduced the viscosity of tracheobronchial mucus in animals made bronchitic by H2SO4 aerosol and markedly increased mucoproduction in healthy animals. Nesosteine was more active than the best known mucolytic/mucoregulatory drugs, such as sobrerol, N-acetylcysteine, bromexine, ambroxol, S-carboxymethylcysteine and mercaptopropionylglycine. The fluidifying activity of the drug was also demonstrated in vitro (pig's gastric mucin), although this proved to be less marked than in vivo...
1986: Drugs Under Experimental and Clinical Research
R Scuri, P Giannetti, A Paesano
The effect of erdosteine and its metabolites on tracheobronchial mucus production and transport was studied. Erdosteine showed important muco-regulating action (increase of mucus production), and also influenced muciliary clearance. Erdosteine, after intravenous administration, was more active than the muco-regulating drugs used for comparative purposes (about 4 times as active as N-acetyl-cysteine; about 1.8 times as active as sobrerol and bromexine; and about 1.4 times as active as ambroxol). After oral administration erdosteine showed significant action on mucus production, causing an effect quantitatively the same as that produced by bromexine...
1988: Drugs Under Experimental and Clinical Research
P Bavaro, P Biscari
The Authors consider the high number of patients who are affected with chronic obstructive bronchitis due to various factors (cigarettes smoking, infections, pollution, reduced immune response). These patients, when submitted to middle-high abdominal surgery in total anaesthesia of middle-long duration, are at increased risk due to pulmonary complications. Therefore, an adequate respiratory protection is necessary; actually it is possible with high dose of Ambroxol (1 g). Two groups, both of 35 patients, were compared; the first group was treated with Ambroxol 1 g the second one with aminophilline, bromexine, B2 adrenergic agonists, corticosteroids...
October 1989: Il Giornale di Chirurgia
R Scuri, P Giannetti, A Paesano
IRFI 016 has demonstrated significant antioxidant activity, inhibiting hepatic lipid peroxidation (rat intoxicated by CCl4) and the formation of gastric lesions by ethanol (rat). This activity proved equal to or better than that exhibited by the most investigated antioxidant/radical scavenger agents (such as BHA, BHT, Vitamin E). The drug markedly increased mucus production (rabbit, mouse) by all the administration routes used (os, i.v. and inhalatory) and proved more active than, or overlapping, the most noted mucoregulatory/mucolytic drugs (sobrerol, bromexine, thiopronine, ambroxol, N-acetylcysteine) which were chosen for comparison...
1990: Drugs Under Experimental and Clinical Research
P Cerutti, Y Kapanci
50 Wistar rats were divided into 5 groups: 4 experimental and 1 control group. The experimental groups A and B received, per os, a daily dose of 100 mg of Na 872 (metabolite VIII of Bromexine) for 3 or 6 days and were killed 1 day later. The experimental groups C and D received 200 mg of the same substance according to the same experimental procedure and for the same periods. The lungs were fixed in situ by perfusion, examined by light and electron microscopy using morphometric methods. No manifest lesions occurred in alveolar tissue...
1979: Respiration; International Review of Thoracic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"